Medicament for improving drug resistance of solid tumors against anti-vascular drugs and application of CPT1a inhibitor in medicament
An inhibitor and drug resistance technology, applied in antitumor drugs, drug combinations, medical preparations containing active ingredients, etc. effect of effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0066] Example 1: Co-treatment of tumors with antivascular drugs and CPT1a shRNA transfection vector in fat environment
[0067] Firstly, the CPT1a shRNA transfection vector was constructed: the Cpt1shRNA lentiviral particles transfected with Cpt1shRNA were used as the CPT1a shRNA transfection vector, which was purchased from Santa Cruz Biotechnology (California). The transduction process was performed according to the manufacturer's protocol provided by the company, and the CPT1a shRNA transfection vector can inhibit the expression of Cpt1 protein.
[0068] pair to about 1 x 10 5 MC38 and Hepa1-6 cells grown in a 12-well plate were grown at a density of 5×10 4 Cpt1shRNA transfection Cpt1shRNA lentiviral particle infection. Cells transduced with lentivirus were then selected with puromycin (2 μg / mL), and the knockdown efficiency of CPT1 was verified by standard quantitative real-time polymerase chain reaction (qPCR) method.
[0069] When constructing a specific CRC liver me...
Embodiment 2
[0074] Example 2: Co-treatment of tumors with antivascular drugs and CPT1a inhibitor drug carriers in fat environment
[0075] Constructing a CPT1a inhibitor drug carrier: the details are as follows: Etomoxir is dissolved in water to obtain a CPT1a inhibitor drug carrier solution.
[0076] When constructing the cell model, MC38 cells were seeded on a 96-well plate at a density of 2500 cells / well, and incubated in 100 μL of the above medium for 24 hours, and a hypoxic environment was provided to each well using a hypoxia kit ( Tumor cells will use free fatty acids in a hypoxic environment), and on the third day, each well was divided into the following groups: free fatty acids (FFA) and Etomoxir were not added (negative control group); only FFA was added; FFA and 50 μM Etomoxir were added ; FFA and 100 μM Etomoxir were added. Tumor cell growth in each well was assessed using the MTT assay system described above. Metabolism of tumor cells was determined using a hippocampal cel...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com